ReviewPhotodermatology, photoimmunology & photomedicine2026
Beyond Tint: Active Ingredient Strategies for Post-Inflammatory Hyperpigmentation due to Visible Light in Skin of Color.
Review in Photodermatology, photoimmunology & photomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Tint: Active Ingredient Strategies for Post-Inflammatory Hyperpigmentation due to Visible Light in Skin of Color.Photodermatology, photoimmunology & photomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-inflammatory hyperpigmentation (PIH) is among the most burdensome sequelae of inflammatory dermatoses in skin of color (SOC), and reduction of visible pigmentation represents the primary clinical outcome of interest. Tinted sunscreens containing iron oxides and/or pigmentary titanium dioxide are currently the best-evidenced strategy for preventing visible light-driven PIH in SOC. However, cosmetic unacceptability-including white cast, poor shade match, and texture incompatibility with acne-prone skin-significantly limits real-world adherence. This concept paper proposes a clinical reframing: when pigment-based visible light filters are not tolerated, pigmentation reduction may be achievable through proactive topical actives with direct anti-pigmentation activity.
methodsThis commentary synthesizes the mechanistic and clinical literature on high-energy visible light (HEVL)-driven pigmentation in SOC, with particular focus on the opsin-3-MITF-melanogenesis axis and topical actives with demonstrated anti-pigmentation activity against HEVL-induced melanogenesis. Evidence is presented to support a proposed clinical reframing and pragmatic algorithm.
resultsHEVL activates opsin-3 on melanocytes, upregulating MITF and promoting formation of stable, autophagy-resistant melanosomes-a mechanism distinct from UVA-driven photooxidation and particularly relevant in darker phototypes. Four prototypical actives with direct clinical or preclinical evidence against HEVL-induced pigmentation are reviewed.
conclusionPigmentation reduction-rather than the mechanism by which it is achieved-should be recognized as the primary clinical endpoint in photoprotection for PIH in SOC. When pigment-based visible light filters containing iron oxides and/or pigmentary titanium dioxide are cosmetically unacceptable, a strategy combining broad-spectrum UVA1 photoprotection with a topical active with anti-pigmentation activity represents a rational, evidence-informed alternative that keeps the clinical goal firmly in focus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.